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Abstract 
Background: Objective of the present cross-sectional study was to investigate the impact of caffeine consumption 
on fatty liver and serum alanine aminotransferase (ALT) concentrations in a random population sample.
Methods: All subjects (n = 1452; 789 women, 663 men; average age 42.3 ± 12.8 years) underwent ultrasonographic 
examination of the liver and completed a standardized questionnaire regarding personal and lifestyle data, in particu-
lar relating to coffee consumption and past medical history. In addition, anthropometric data were documented and 
laboratory examinations performed. Statistical interpretation of the data was performed descriptively and by means 
of bivariate and multivariate analysis.
Results: Data of the present study demonstrated a significant association between hepatic steatosis male gender 
(p < 0.0001), advanced age (p < 0.0001) and elevated body-mass index (BMI; p < 0.0001). No association between caf-
feine consumption and fatty liver was identified. An association between caffeine consumption and elevated serum 
ALT concentrations was not identified.
Conclusions: The findings of the present study provide no evidence for an association between caffeine consump-
tion and either the prevalence of hepatic steatosis or serum ALT concentrations.
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Background
Non-alcoholic fatty liver disease (NAFLD) is the most 
frequent and most important liver disorder worldwide 
[1]. The increase in overweight, type-2 diabetes melli-
tus and dyslipidemia has reached epidemic proportions. 
The development of NAFLD is closely associated with 
all three of these disorders [2]. The spectrum of NAFLD 
extends from simple deposits of fat in the liver to non-
alcoholic steatohepatitis (NASH), fibrosis and, ultimately, 
cirrhosis. Histology reveals triglyceride-containing fat 
vesicles within the hepatic parenchyma that are char-
acteristic of simple fat deposits; NASH is characterized 
by inflammatory infiltrates and cell destruction [3]. In 
cirrhosis, scar tissue replaces the degenerated hepatic 
parenchyma.
Fatty liver is diagnosed using imaging methods such 
as ultrasonography (US), and magnetic resonance imag-
ing (MRI). MRI is superior to ultrasound in detecting 
fatty liver, especially when the degree of hepatic steatosis 
is mild. Using ultrasound is practical and cost-effective 
and is associated with a sensitivity of 83 % and specifity 
of 100 % if at least 30 % of the liver has been affected by 
fat accumulation and has been shown to be very valuable 
clinically in assessing the fat content of the liver [4].
Laboratory parameters, such as an elevated transami-
nase quotient (aspartate transaminase (AST)/alanine 
transaminase (ALT)) or a depressed adiponectin con-
centration can provide some assistance in distinguishing 
steatohepatitis from simple fatty liver [5]. Liver biopsy 
with histological examination remains, however, the gold 
standard for diagnostic confirmation [6, 7].
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Coffee is one of the most widely consumed beverages 
worldwide [8]. Beneficial effects of coffee consumption 
have been demonstrated for a wide variety of disorders, 
including Parkinson’s disease, diabetes mellitus, colorec-
tal carcinoma, coronary artery disease, liver diseases and 
suicidality [9, 10]. Coffee consumption appears to even 
reduce mortality [9, 10].
Coffee consumption has its beneficial impact par-
ticularly on diseased or pathologically altered hepatic 
parenchyma. Several studies have shown that coffee con-
sumption is associated with a less pronounced degree of 
fibrosis or cirrhosis of the liver [11–14], a lower bright 
liver score (BLS) [11, 15] and a lower prevalence and 
reduced severity of NAFLD [11, 16]. Furthermore, a 
number of studies have uncovered evidence that coffee 
consumption appears to associated with a lower concen-
tration of ALT [17–19]. The influence of coffee consump-
tion in hepatitis B patients remains controversial [20, 21].
To our knowledge, no studies of the effects of coffee 
consumption of hepatic steatosis and ALT concentrations 
in non-selected populations have been published. Objec-
tive of the present study was to investigate this potential 




The EMIL Study (Echinococcus multilocularis and 
other Internal medical disorders in Leutkirch) was con-
ducted in 2002 to investigate the respective prevalences 
of Echinococcus multilocularis infection and other 
disorders in the southwest German city of Leutkirch 
[22]. A total of 4000 registered inhabitants between the 
ages of 10 and 65 years received invitations by mail to 
participate in a random population-based sample. Of 
these, 2445 persons provided their written consent and 
were examined for the study. In order to determine the 
effects of coffee consumption on hepatic steatosis, cer-
tain exclusion criteria were established. Excluded from 
the study were all minors; all subjects with history of 
hepatitis B or C, or of hemochromatosis and all sub-
jects reporting alcohol abuse (males, ≥40 g/d; females, 
≥20 g/d). Also excluded were any subjects with incom-
plete data sets. The resulting study collective thus 
included 1452 subjects (Fig. 1).
Quantification of caffeine consumption
Subjects’ consumption of caffeinated beverages such as 
coffee and black tea was assessed using a standardized 
questionnaire. Quantification of caffeine intake was 
based on the following categories: more than once a 
day, daily, less than weekly, less than monthly, seldom/
rarely.
Hepatic steatosis, ultrasonographic criteria
Four identical HDI 5000 units (ATL Ultrasound, Philips 
Medical Systems, Bothell, WA, USA) were used. The 
diagnosis of hepatic steatosis was made according to 
criteria proposed by Charatcharoenwitthaya based on a 
comparison of the hepatic and renal parenchyma, taking 
into consideration the dorsal attenuation, penetration of 
the diaphragm and ability to assess the liver vessels. The 
severity of the disease is defined as no steatosis and stea-
tosis grade I, II and III [23, 24]. Due to the small number 
of cases in group III, these subjects were combined with 
those in group II for the statistical analysis.
Laboratory tests and procedures
Laboratory blood testing included analytical clinical 
chemistry for liver enzymes, lipids and other biochemi-
cal values were determined using the Dimension XL unit 
(Dade Behring Inc., Newark, DE, USA).
Metabolic syndrome: criteria
Metabolic syndrome was defined according to modi-
fied ‘US National Cholesterol Education Program Adult 
Treatment Panel III’ criteria, whereby at least three of 
the following criteria had to be met: Obesity with body-
mass index (BMI) over 30 kg/m2; serum triglyceride (TG) 
concentration ≥1.69  mmol/l; serum high-density lipo-
protein (HDL) cholesterol <1.29 mmol/l for women and 
<1.04 mmol/l for men; history of hypertension and ran-
dom blood glucose >8.88 mmol/l or confirmed diabetes 
mellitus [24].
Statistical analysis
The statistical analysis and calculations were performed 
with the SAS statistical software program (version 9.2). 
First, data were analyzed descriptively: for qualitative 
variables, the relative and absolute frequency were cal-




• Age < 18 (n=258)
• Hepatitis B oder C infection(n=30)
• Haemochromatosis (n=1)
• high alcohol consumption (n=240)
• Missing data (n=583)
Fig. 1 Flow of the subject across the study
Page 3 of 6Graeter et al. BMC Res Notes  (2015) 8:640 
deviation. In order to detect differences between subjects 
with and without hepatic steatosis, the Wilcoxon rank-
sum test was used for continuous variables, while for 
categorical variables, the Chi-Square test were used. Uni-
variate logistic regression was used to assess the associa-
tion between caffeine consumption and hepatic steatosis. 
Multivariate logistic analysis was performed to evaluate 
the association between hepatic steatosis and caffeine 
consumption as well as other risk factors like age, BMI, 
gender, metabolic syndrome and physical activity. To 
assess the association between elevated ALT concentra-
tions and coffee consumption univarite and multivariate 
logistic regression analysis was used.
All tests were two-tailed. Statistical significance was set 
at α = 0.05. The P value was given to four decimal places, 
while the odds ratio (OR) and 95  % confidence interval 
(CI) were given to three decimal places.
Ethical agreement and informed consent
The study meets the criteria of the revised version of 
the World Medical Association Declaration of Helsinki 
(2000) concerning ethical principles for medical research 
involving human subjects and was approved by the eth-
ics committee of the State Medical Association of Baden-




The data of 1452 subjects [789 women (54.3  %), 663 
men (45.7  %), average age 42.3  ±  12.8  years (range 
18–65  years)] were analyzed in the present study. The 
majority of the subjects were of German nationality 
(89.9  %). The mean waist-to-hip ratio (WHR) stood at 
0.8 ± 0.1, the mean BMI was 25.6 ± 4.7 kg/m2. Criteria 
for metabolic syndrome were met in 5.9  % of subjects. 
Hepatic steatosis was diagnosed in 381 subjects (26.2 %) 
and is more common in men (34.8 %, n =  231) than in 
women (19.0 %, n = 150). The difference in the frequency 
of hepatic steatosis between men and women was sta-
tistically significant (p  <  0.0001). Grade I steatosis was 
identified in 163 subjects (11.2 %), and grade II/III stea-
tosis was identified in 218 subjects (15.0 %; Fig. 2). Sub-
jects with hepatic steatosis had higher BMI, waist-to-hip 
ratio (WHR) and transaminase levels (ALT, AST, GGT; 
Table 1). Elevated ALT concentrations were identified in 
198 (13.6 %) subjects.
In all, 76.2  % of subjects consumed caffeine at least 
daily. In our study collective, there was no statistically 
significant difference between the sexes in terms of caf-
feine consumption (p = 0.1748). In the univariate analy-
sis, a significant association could be identified between 
caffeine consumption and hepatic steatosis (p = 0.0461) .
Multivariate logistic analysis was performed to evalu-
ate the association between hepatic steatosis and caf-
feine consumption as well as other risk factors like age, 
BMI, gender, metabolic syndrome and physical activity. 
The results show a significant association of heaptic stea-
tosis with gender, age and BMI (p < 0.0001). A relation-
ship between hepatic steatosis and caffeine consumption 
could not be shown (p = 0.8144, Table 2).
In a further analysis, the impact of coffee on ALT con-
centrations was assessed. Both in the univariate analysis 
and after adjusting for gender, age and BMI, there is no 
significant association between coffee consumption and 
elevated ALT concentrations (p  =  0.7495; p  =  0.7905; 
Table 3).
Discussion
To date to our knowledge, no prospective, sonographic 
studies of the association between coffee consump-
tion and NAFLD in large population-based collectives 
have been published. Previous community-based stud-
ies have investigated collectives with small numbers 
of subjects [13, 15] or have been retrospective and did 
not employ diagnostic ultrasonography [16]. Birerdinc 
et al. retrospectively analyzed 18,550 datasets from the 
NHANES study. The diagnosis of NAFLD, however, 
was made exclusively on the basis of elevated transami-
nase concentrations. Subjects in the NAFLD group 
consumed significantly less coffee than did the control 
group (p =  0.0003) [16]. Studies of elevated ALT con-
centrations showed significant differences with respect 
to the populations studied and do not permit any defini-
tive conclusions regarding NAFLD as a cause of the 
ALT elevation [25]. The findings of this study, therefore, 
cannot be compared with our findings. Molloy et  al. 
examined a patient collective using both ultrasonogra-
phy and biopsy, and found that increased coffee con-
sumption was associated with a reduced risk of liver 
fibrosis in patients with NASH [13]. For ethical reasons, 
histological diagnosis of NASH cannot be justified in a 
population-based study; hence, these data also cannot 
be directly compared with our own.
In a case–control study of a collective of 130 individu-
als (with and without hepatic steatosis in n  =  73 and 
n  =  57 subjects, respectively), Gutiérrez-Grobe et  al. 
made the diagnosis of NAFLD solely on the basis of 
ultrasonographic criteria. As in our study, the severity of 
hepatic steatosis was divided into four grades. The find-
ings of the study failed to demonstrate an unequivocal 
anti-oxidant effect of coffee though patients with higher-
grade steatosis drank more coffee than did those with less 
severe steatosis [26].
In a study of 157 patients and 153 controls, Cata-
lano et  al. made the diagnosis of hepatic steatosis using 
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different exclusion criteria. Coffee consumption was 
monitored over a follow-up period of 6 months. The 
authors thus ascribe a possible protective effect to 
elevated coffee consumption. Their data, however, were 
derived from a highly selected collective drawn from 






































Fig. 2 Caffeine consumption in relation to the severity of hepatic steatosis
Table 1 Demographics and other characteristics of subjects with and without hepatic steatosis
Significant p values are in italics
STD standard deviation, BMI body-mass index, ALT alanine transaminase, AST aspartate transaminase, GGT gamma-glutamyl transferase
Hepatic steatosis not diagnosed (n = 1071, 
mean ± STD)




 Female 639 (59.7 %) 150 (39.4 %) 789 (54.3 %) <0.0001
 Male 432 (40.3 %) 231 (60.6 %) 663 (45.7 %)
Age 39.9 ± 12.4 49.0 ± 11.4 42.3 ± 12.8 <0.0001
BMI 24.1 ± 3.8 29.8 ± 4.7 25.6 ± 4.7 <0.0001
Waist/hip-ratio 0.8 ± 0.1 0.9 ± 0.1 0.8 ± 0.1 <0.0001
Coffee consumption, n (%)
 More than once a day 209 (19.5 %) 72 (18.9 %) 281 (19.4 %)
 Daily 587 (54.8 %) 237 (62.2 %) 824 (56.8 %)
 Less than weekly 86 (8.0 %) 26 (6.8 %) 112 (7.7 %)
 Less than monthly 45 (4.2 %) 7 (1.8 %) 52 (3.6 %) 0.0408
 Seldom/rarely 144 (13.5 %) 39 (10.2 %) 183 (12.6 %)
ALT 13.3 ± 5.6 20.0 ± 10.6 15.1 ± 7.8 <0.0001
AST 8.9 ± 2.4 11.0 ± 5.1 9.5 ± 3.5 <0.0001
GGT 11.0 ± 11.0 19.1 ± 20.3 13.2 ± 14.5 <0.0001
Metabolic syndrome, n (%)
 No 1050 (98.0 %) 317 (83.2 %) 1367 (94.2 %) <0.0001
 Yes 21 (2.0 %) 64 (16.8 %) 85 (5.9 %)
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outpatient clinic and cannot be applied to the general 
population [15].
In our study population, elevated ALT concentrations 
were identified in 13.6  % of subjects. This corresponds 
with the finding of another cross-sectional study from 
China (10.8  %) [25]. Studies published to date have 
shown an inverse relationship between coffee con-
sumption and serum ALT concentrations. The findings 
of our population-based study failed to demonstrate a 
corresponding association between caffeine consump-
tion and serum ALT concentrations. It is to be noted 
that, in the other studies, the diagnosis of NAFLD was 
not based on imaging of the liver; furthermore, some of 
these studies were performed in highly selected popula-
tions [19, 27].
The present study does have some important limita-
tions. Due to the choice of study design, we were able to 
investigate associations but not causalities. The diagno-
sis of hepatic steatosis was made on the basis of ultra-
sonographic criteria. Liver biopsy, the current gold 
standard for confirming a diagnosis of NAFLD, was not 
performed. Furthermore, data on caffeine consumption 
were obtained only on one occasion. In addition, the 
dual effect of coffee consumption was not investigated 
further.
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Table 2 Logistic regression analysis to  assess the asso-
ciation between hepatic steatosis and caffee consumption 
and other influencing factors
Significant p values are in italics
CI confidence interval, Ref. reference group
Odds ratio (95 % CI) p value
Gender <0.0001
 Female Ref.
 Male 2.775 (2.047–3.764)
Age 1.053 (1.039–1.066) <0.0001
BMI 1.324 (1.271–1.380) <0.0001
Metabolic syndrome
 No Ref. Ref.
 Yes 0.906 (0.501–1.640) 0.0668
Coffee consumption
 More than once a day 0.771 (0.443-1.343)
 Daily 0.809 (0.496-1.318)
 Less than weekly 0.749 (0.368–1.526) 0.8144




 0–2 h/week 1.021 (0.719–1.449) 0.9187
 2–4 h/week 0.931 (0.612–1.419)
 4–10 h/week 0.937 (0.548–1.603)
 >10 h/week 0.581 (0.169–2.001)
Table 3 Regression analysis to  assess the association 
between  coffee consumption and  elevated alanine 
transaminase levels (ALT)
CI confidence interval, Ref. reference group
Coffee consumption Odds ratio (95 % CI) p value
Univariate
More than once a day 1.097 (0.617–1.953)
Daily 1.302 (0.794–2.135)
Less than weekly 1.380 (0.694–2.746) 0.7495
Less than monthly 1.006 (0.384–2.640)
Seldom/rarely Ref.
After adjusting for age, gender and BMI
More than once a day 0.773 (0.447–1.339)
Daily 0.806 (0.497–1.308) 0.7905
Less than weekly 0.722 (0.355–1.467)
Less than monthly 0.554 (0.190–1.613)
Seldom/rarely Ref.
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